NAGE Niagen Bioscience, Inc.

BUSINESS SUMMARY

Niagen Bioscience (formerly ChromaDex) is the producer and licensor of nicotinamide riboside (NR) — a vitamin-B3 derivative sold as the consumer brand Tru Niagen and as a licensed ingredient (Niagen) to other supplement-and-functional-food brands. NR is the company's proprietary form of NAD+ precursor, a category positioned around healthy-aging and cellular-energy claims.

Revenue mix is direct-to-consumer Tru Niagen sales, wholesale ingredient licensing to consumer-product manufacturers, and clinical/healthcare-channel revenue. The business holds patents and process IP around the NR molecule that has been the subject of multi-year litigation against alternative-NMN producers.

The company rebranded from ChromaDex to Niagen Bioscience in 2024, signaling tighter brand-and-product focus.

MARKET OPPORTUNITY

The NAD+-precursor consumer-supplement category is one of the fastest-growing healthy-aging-positioning segments:

• Direct-to-consumer Tru Niagen is the brand-led growth driver; recurring-subscription customers drive predictable revenue
• Ingredient-licensing generates higher-margin recurring revenue from consumer brands integrating Niagen into their formulations
• Clinical and prescription-adjacent channels are smaller but represent higher-credibility positioning

Macro context: revenue growth of 30% YoY reflects sustained category demand plus brand-equity from the NR-vs-NMN scientific literature debate where Niagen has positioned itself as the safer, more clinically-validated option.

REVENUE QUALITY

The economics reflect a branded-supplement plus IP-licensing business:

• Gross margin 64% — strong for consumer supplements; reflects the proprietary-ingredient pricing advantage
• Operating margin — TTM positive
• Revenue $129M TTM — meaningful scale
• P/S ~3 — reflects category-growth optimism plus IP-defensibility premium

COMPETITIVE ADVANTAGE

The defensible asset is the NR-molecule patent estate plus the Tru Niagen brand:

• NR-process patents that have survived multi-year litigation challenges
• Tru Niagen brand recognition in the healthy-aging consumer category
• Clinical-research relationships with academic institutions that validate NR's mechanism

What it is not: a moat against NMN supplements. NMN is a direct competitor molecule with its own clinical advocates; consumer migration between NR and NMN can shift category share rapidly.

GROWTH THESIS

Three things have to work:

1. NR-vs-NMN consumer narrative holds. Niagen has positioned NR as the safer, more clinically-validated option; if the FDA further restricts NMN, that's a tailwind. If NMN clears all regulatory questions, competitive pressure increases.
2. Ingredient-licensing channel continues to scale — high-margin recurring revenue with multi-year customer life.
3. International expansion compounds — Tru Niagen is well-established in the US; international markets remain growth optionality.

KEY RISKS

Three specific risks:

1. NMN regulatory clarification. Currently NMN is in regulatory limbo in the US; a favorable NMN ruling would compress NR's positioning advantage.

2. Patent-defensibility erosion. Niagen's IP estate has survived past challenges, but each new challenge requires capital and management attention.

3. Consumer-supplement-category sentiment shift. Healthy-aging supplements are a discretionary category; a recession or category-skepticism cycle compresses across all category players.

VERDICT

The 84.5/100 score captures the brand-plus-IP-defensibility combination at meaningful scale and the category-growth tailwind. The premium reflects the IP moat versus generic supplement peers.

For investors who want consumer-supplement-category exposure with brand-and-IP-defensibility, NAGE is one of few liquid public-market vehicles in the NAD+-precursor segment. For investors avoiding consumer-discretionary or supplement-category sentiment risk, the category exposure is the disqualifying constraint.

The single metric to watch next is ingredient-licensing revenue percentage quarter-over-quarter. Higher recurring-licensing mix improves multiple-defensibility versus pure DTC-supplement exposure.